Teleflex (NYSE:TFX) updated its FY20 earnings guidance on Thursday. The company provided earnings per share guidance of $12.50-12.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.68. The company issued revenue guidance of $2.764-2.790 billion, compared to the consensus revenue estimate of $2.78 billion.Teleflex also updated its FY 2020
Pre-Market guidance to 12.50-12.70 EPS.
A number of analysts recently weighed in on TFX shares. UBS Group upped their price objective on shares of Teleflex from $430.00 to $440.00 and gave the stock a buy rating in a research note on Friday. Morgan Stanley upped their price objective on shares of Teleflex from $392.00 to $405.00 and gave the stock an overweight rating in a research note on Tuesday, December 17th. Piper Sandler upped their price objective on shares of Teleflex from to in a research note on Friday. Stephens upped their price objective on shares of Teleflex from $400.00 to $425.00 and gave the stock an overweight rating in a research note on Friday. Finally, Raymond James upped their price objective on shares of Teleflex from $415.00 to $450.00 and gave the stock a strong-buy rating in a research note on Friday. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $406.33.
Shares of TFX traded down $13.96 during mid-day trading on Friday, hitting $370.40. 308,692 shares of the company traded hands, compared to its average volume of 171,218. Teleflex has a 1-year low of $271.56 and a 1-year high of $398.65. The company has a quick ratio of 1.44, a current ratio of 2.32 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $17.79 billion, a PE ratio of 37.87, a price-to-earnings-growth ratio of 2.12 and a beta of 0.94. The business has a 50 day moving average of $380.28 and a 200 day moving average of $357.03.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 20th. The medical technology company reported $3.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $0.06. Teleflex had a net margin of 17.78% and a return on equity of 18.97%. The firm had revenue of $681.00 million for the quarter, compared to the consensus estimate of $679.01 million. During the same quarter in the prior year, the company posted $2.77 earnings per share. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. As a group, research analysts expect that Teleflex will post 12.68 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $1.36 annualized dividend and a dividend yield of 0.37%. Teleflex’s dividend payout ratio (DPR) is currently 12.20%.
In related news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $346.63, for a total value of $69,326.00. Following the transaction, the director now owns 936 shares in the company, valued at approximately $324,445.68. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Cameron P. Hicks sold 1,300 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $350.00, for a total transaction of $455,000.00. Following the completion of the transaction, the vice president now owns 6,106 shares in the company, valued at approximately $2,137,100. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,700 shares of company stock worth $2,342,968. Corporate insiders own 2.36% of the company’s stock.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: Trading Penny Stocks
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.